Omnicell Inc. (OMCL)
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.
Here's Why Omnicell (OMCL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth
Omnicell highlights Titan XT and OmniSphere momentum, and raises profit outlook, while customer approval timing weighs on product bookings.
Omnicell Q2 Earnings Call Highlights
Omnicell NASDAQ: OMCL reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform investments.
Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript
Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript
Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.
Should You Continue to Hold OMCL Stock in Your Portfolio Now?
Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.
What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?
Shares of Omnicell OMCL have rallied 52.6% over the past year, significantly outperforming the industry's 20.8% fall and the S&P 500 composite's 23.9% gain.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Do Options Traders Know Something About Omnicell Stock We Don't?
Investors need to pay close attention to OMCL stock based on the movements in the options market lately.
